Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE: HIMS) and its peers.

Healthcare technology companies develop software, data analytics, and digital platforms supporting clinical operations, administrative functions, and patient engagement across healthcare systems. Tailwinds include healthcare digitization driving demand for electronic health records, telehealth platforms, and AI-powered diagnostic tools. Regulatory incentives promote interoperability and data sharing, while labor shortages increase automation demand. Headwinds include lengthy sales cycles with risk-averse healthcare buyers, complex regulatory requirements including data privacy compliance, and integration challenges with legacy systems. Competition from established technology giants entering healthcare and reimbursement uncertainties for digital health solutions add market complexity.Add to Conversation

The 7 healthcare technology stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 1.8% while next quarter’s revenue guidance was in line.

Luckily, healthcare technology stocks have performed well with share prices up 17.2% on average since the latest earnings results.

Hims & Hers Health (NYSE: HIMS)

Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE: HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.

Hims & Hers Health reported revenues of $617.8 million, up 28.4% year on year. This print was in line with analysts’ expectations, but overall, it was a mixed quarter for the company with full-year revenue guidance exceeding analysts’ expectations but revenue guidance for next quarter missing analysts’ expectations significantly.

“More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we’re well on our way to becoming the global leader in consumer health,” said Andrew Dudum, co-founder and CEO.

Hims & Hers Health scored the highest full-year guidance raise of the whole group. The company added 40,000 customers to reach a total of 2.51 million. Unsurprisingly, the stock is up 72.7% since reporting and currently trades at $26.79.

Is now the time to buy Hims & Hers Health? Access our full analysis of the earnings results here, it’s free.

Best Q4: Privia Health (NASDAQ: PRVA)

Operating in 13 states and the District of Columbia with over 4,300 providers serving more than 4.8 million patients, Privia Health (NASDAQ: PRVA) is a technology-driven company that helps physicians optimize their practices, improve patient experiences, and transition to value-based care models.

Privia Health reported revenues of $541.2 million, up 17.4% year on year, outperforming analysts’ expectations by 4.8%. The business had a stunning quarter with a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

The market seems content with the results as the stock is up 3.5% since reporting. It currently trades at $23.45.

Is now the time to buy Privia Health? Access our full analysis of the earnings results here, it’s free.

Weakest Q4: GoodRx (NASDAQ: GDRX)

Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ: GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.

GoodRx reported revenues of $194.8 million, down 1.9% year on year, exceeding analysts’ expectations by 0.8%. Still, it was a softer quarter as it posted full-year revenue guidance missing analysts’ expectations significantly and full-year EBITDA guidance missing analysts’ expectations significantly.

As expected, the stock is down 5.7% since the results and currently trades at $2.31.

Read our full analysis of GoodRx’s results here.

Tandem Diabetes (NASDAQ: TNDM)

With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ: TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels.

Tandem Diabetes reported revenues of $290.4 million, up 15% year on year. This print surpassed analysts’ expectations by 4.9%. Taking a step back, it was a satisfactory quarter as it also produced a beat of analysts’ EPS estimates but full-year revenue guidance missing analysts’ expectations significantly.

Tandem Diabetes scored the biggest analyst estimates beat but had the weakest full-year guidance update among its peers. The stock is up 13.1% since reporting and currently trades at $20.94.

Read our full, actionable report on Tandem Diabetes here, it’s free.

Evolent Health (NYSE: EVH)

Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE: EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.

Evolent Health reported revenues of $468.7 million, down 27.5% year on year. This result was in line with analysts’ expectations. Overall, it was a strong quarter as it also produced a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

Evolent Health had the slowest revenue growth among its peers. The stock is up 12.7% since reporting and currently trades at $2.88.

Read our full, actionable report on Evolent Health here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.